SOURCE: Masimo

Masimo

Masimo

March 06, 2014 08:00 ET

Flagler Hospital Upgrades to Masimo SET® Pulse Oximetry for Improved Patient Outcomes

ST AUGUSTINE, FL and IRVINE, CA--(Marketwired - Mar 6, 2014) - Masimo (NASDAQ: MASI) today announced that Flagler Hospital -- ranked among the top 5% of all hospitals in the nation for both clinical excellence and patient safety for the past eight consecutive years -- has upgraded system-wide to Masimo SET® pulse oximetry, the standard-of-care at leading hospitals around the world.

Flagler Hospital joins a growing and distinguished roster of health organizations using Masimo SET® pulse oximetry, clinically shown to virtually eliminate false alarms1 and help clinicians detect life-threatening events.2 Flagler Hospital's standardization to Masimo SET® pulse oximetry is in keeping with the healthcare organization's dedication to excellence in care and delivering the best possible results for its patients.

"Since Flagler Hospital began using Masimo pulse oximeters, we have seen quite a difference in the level of performance," said Jim Clifton, BioMed Supervisor at Flagler Hospital. "We have far fewer nuisance alarms than before, and we are able to obtain accurate readings, even when patients are moving or have low perfusion." 

The performance of Masimo SET® pulse oximetry is proven by more than 100 independent and objective studies and thousands of clinical evaluations. Masimo SET® is trusted by clinicians to safely monitor more than 100 million patients each year and is used hospital-wide by eight of the top 10 hospitals on the U.S. News & World Report Best Hospitals Honor Roll (2013-2014). Compared to other pulse oximeters, during patient motion and low perfusion, Masimo SET® provides measurements when other pulse oximeters cannot, dramatically reduces false alarms (specificity), and accurately detects true alarms (sensitivity)1 that can indicate a deteriorating patient. Most important, Masimo SET® pulse oximetry has been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP)3 in neonates, screen newborns for critical congenital heart disease (CCHD),4,5 reduce ventilator weaning time and arterial blood gas measurements in the ICU,6 and save lives and costs while reducing rapid response activations and intensive care unit transfers on the general floor.7

"We are honored to partner with Flagler Hospital, which has a well-deserved reputation for having patient empathy and providing quality care," said Masimo Founder and CEO Joe Kiani. "We also appreciate and share Flagler Hospital's commitment to excellence and look forward to helping this great hospital and staff meet and exceed their patient-care needs."

1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
3 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
4 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
5 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.
6 Durbin, et al. Critical Care Medicine. 2002 Aug.;30(8): 1735 to 1740.
7 Taenzer A, et al. Anesthesiology, 2010 Feb;112(2):282-7.

About Flagler Hospital
Flagler Hospital is a 335 bed, acute care hospital that has been ranked among the top 5% of all hospitals in the nation for both clinical excellence and patient safety for the past eight consecutive years. The hospital has operated as a not-for-profit healthcare institution in St. Augustine, Florida since its founding in 1889. Flagler Hospital's focus on quality has resulted in numerous national accreditations including, designation as a Chest Pain Center by the Society of Chest Pain Centers, ANCC Magnet Status for Nursing Excellence, the Gold Seal of Approval™ from The Joint Commission for Primary Stroke Care Centers, National accreditation for its total hip and total knee replacement programs, accreditation of its Cancer Institute by the Commission on Cancer and ASMBS Center of Excellence Designation for its Bariatric Surgery Center. To learn more about all of the hospital's services log on to www.FlaglerHospital.org.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that the hospital-wide conversion ensures that all Flagler Hospital patients will be cared for using the most technologically and clinically advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our assumptions regarding the repeatability of clinical results; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.

Contact Information